Giles Richard Platford Sells 31,083 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Richard Platford sold 31,083 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $531,519.30. Following the transaction, the insider owned 315,838 shares of the company’s stock, valued at approximately $5,400,829.80. This represents a 8.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

NYSE:TAK traded down $0.06 during trading hours on Wednesday, hitting $17.42. The stock had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. The business’s 50 day moving average is $16.49 and its 200-day moving average is $17.13. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on TAK shares. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TAK. Valeo Financial Advisors LLC acquired a new stake in Takeda Pharmaceutical in the 2nd quarter valued at $163,000. GAMMA Investing LLC increased its position in shares of Takeda Pharmaceutical by 10.7% in the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after acquiring an additional 1,338 shares during the last quarter. Versant Capital Management Inc raised its holdings in Takeda Pharmaceutical by 10.8% during the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock worth $684,000 after acquiring an additional 4,169 shares in the last quarter. Parallel Advisors LLC boosted its position in Takeda Pharmaceutical by 10.5% during the first quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after purchasing an additional 2,343 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its stake in Takeda Pharmaceutical by 9.6% in the first quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after purchasing an additional 2,640 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.